Global Kinase Inhibitor In Autoimmune Diseases Market

DelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases – Market Insights and Market Forecast – 2030’ report delivers an in-depth understanding of the market trends of Global Kinase Inhibitor in Autoimmune Diseases across the globe.


The global kinase inhibitor in autoimmune diseases market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted global kinase inhibitor in autoimmune diseases market size from 2018 to 2030, across the globe. The report also covers the current global kinase inhibitor in autoimmune diseases treatment practice, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Global Kinase Inhibitor in Autoimmune Diseases: Disease Understanding and Treatment Algorithm

Global Kinase Inhibitor in Autoimmune Diseases Overview

Immunological disorders are diseases or conditions caused by a dysfunction of the immune system and include allergy, asthma, autoimmune diseases, autoinflammatory syndromes, and immunological deficiency syndromes.


The immune system is a complex network of special cells and organs that defends the body from germs and other foreign invaders. At the core of the immune system is the ability to tell the difference between self and nonself: ’own and ’foreign. A flaw can make the body unable to tell the difference between self and nonself. This is when the body starts making autoantibodies that attack normal cells by mistake. This misguided attack on one’s own body is the damage known as autoimmune diseases. These are more common in women than in men.


Autoimmune diseases can affect anyone. However, certain people at greater risk include; women of childbearing age, people with family history, and people exposed to certain things in the environment like sunlight, chemicals (or solvents), viral and bacterial infections, etc. Each disease is unique; many share hallmark symptoms, such as fatigue, dizziness, low-grade fever, and sometimes inflammation. For many autoimmune diseases, symptoms persist or can be mild and severe. When symptoms go away for a while, it is called remission, while when they occur suddenly and severely, they are called flares.

Inflammation is a biological response to stimuli interpreted by the body to have a potentially harmful effect. While after injury or in certain conditions, inflammation is a normal, healthy response, inflammatory disorders that result in the immune system attacking the body’s cells or tissues may cause abnormal inflammation, which results in chronic pain, redness, swelling, stiffness, and damage to normal tissues.


There are many types of medicines used to treat autoimmune diseases, which depends on the disease present, its severity, and the symptoms. The treatment helps relieve symptoms, replace vital substances that the body can no longer make, and suppress the immune system. The treatment includes anti-inflammatory drugs, corticosteroids, pain-killing medications, immunosuppressants, physical therapy, treatment for deficiency, and surgery. Small molecule tyrosine kinase inhibitors are important contributors to the pharmacological control of a diverse array of diseases, including various malignant processes and immune-mediated diseases such as autoimmune and inflammatory conditions. Among non-receptors tyrosine kinase, safety information from long-term studies of Jak inhibitor treatment is limited due to the novelty of these drugs. Most data are available from RA patients, but there is slowly emerging information from patients with skin inflammation, and several long-term safety-assessing trials are currently recruiting patients


In the immune system, cyclic adenosine monophosphate (cAMP) is well established as a potent regulator of innate and adaptive immune cell functions. Therapeutic strategies to interrupt or enhance cAMP generation or effects have immunoregulatory potential in autoimmune and inflammatory disorders.


Besides the most extensively studied Jak inhibitors, compounds targeting other kinases such as Syk, Src-family kinases, or Btk are also expected to emerge as new therapeutics for inflammatory dermatitis. The more detailed understanding of individual kinase family members and the development of novel inhibitors with more specifically tailored specificities toward individual kinases are expected to lead to more refined therapies driving the field toward personalized targeted therapeutic approaches. Moreover, locally delivered JAK inhibitors can help in increasing patient satisfaction.

Drug Chapters

The drug chapter segment of the Global Kinase Inhibitor in Autoimmune Diseases report encloses the detailed analysis of Global Kinase Inhibitor in Autoimmune Diseases marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps understand the Global Kinase Inhibitor in Autoimmune Diseases clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.


The currently approved Janus Kinase inhibitors include tofacitinib, filgotinib, baricitinib, upadacitinib, and peficitinib which are prescribed to treat diseases like Rheumatoid Arthritis, Ulcerative Colitis, Psoriatic Arthritis, Psoriasis, and Crohn’s Disease.


Xeljanz/Xeljanz XR is a JAK inhibitor that is formulated with the citrate salt of tofacitinib. JAKs are intracellular enzymes that transmit signals from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate intracellular activity, including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. It is approved for RA, PsA, UC, and pcJIA.


Despite immense progress in advancing kinase inhibitors with desirable drug-like properties into the clinic, including inhibitors of JAKs, IRAK4, RIPKs, BTK, SYK, and TPL2, the development of highly selective inhibitors is the most challenging facet of small-molecule discovery.

Products detail in the report…


Global Kinase Inhibitor in Autoimmune Diseases emerging drugs


Ritlecitinib/PF‐06651600 (Pfizer) is an orally bioavailable small molecule that inhibits JAK3 by irreversibly blocking the ATP binding site and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) – part of Tec family of kinases (Bruton’s tyrosine kinase [BTK], bone marrow tyrosine kinase on chromosome X [BMX], interleukin‐2-inducible T-cell kinase [ITK], resting lymphocyte kinase, and TEC) – with high selectivity over the other JAK isoforms, JAK1, JAK2, and Tyk2 and the broader human kinome. The results from 8-week Phase II clinical studies have demonstrated that PF-06651600 (200 mg once daily) was associated with significant improvements in Rheumatoid Arthritis (RA) disease activity and was generally well-tolerated. The drug is also being evaluated in phase II clinical studies for Crohn’s disease (CD), Ulcerative colitis (UC). Ritlecitinib is being evaluated in Phase II clinical studies that aim to assess the efficacy and safety of PF-06650833, PF-06651600, and tofacitinib alone and in combination in participants with moderate-to-severe active RA with an inadequate response to methotrexate.


SHR0302 (Reistone Biopharma) is a novel, potent, orally administered selective Janus kinase 1 (JAK1) inhibitor in development by Reistone Biopharma as a treatment for inflammatory bowel diseases. JAK1 selectivity could potentially provide a favorable safety and efficacy profile compared to the pan-JAK inhibitor. Longer-term clinical studies are ongoing to confirm a favorable risk-benefit of JAK1 selectivity by avoiding the hematological side effects of JAK2 inhibition. Reistone is currently carrying out global multicenter clinical programs of SHR 0302, in both oral and topical dosage forms, for Inflammatory Bowel Diseases (IBD). The drug is being evaluated in phase II clinical study in patients with moderate-to-severe active CD, phase II study in patients with moderate-to-severe active UC, phase III study for RA, and phase II/III for Atopic dermatitis.

Products detail in the report…

Global Kinase Inhibitor in Autoimmune Diseases Market Outlook

The Global Kinase Inhibitor in Autoimmune Diseases market outlook of the report builds a detailed comprehension of the historical, current, and forecasted global kinase inhibitor in autoimmune diseases market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of Global Kinase Inhibitor in Autoimmune Diseases market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the Global Kinase Inhibitor in Autoimmune Diseases market across the globe is expected to change in the study period 2018–2030.


Autoimmune and inflammatory diseases are common and diverse, and they can affect nearly any organ system. Much of the pathogenesis of these diseases is related to deregulated cytokine activity. Historically, autoimmune and inflammatory diseases have been treated with medications that nonspecifically suppress the immune system. Monoclonal antibodies (biologics) that block the action of pathogenic cytokines emerged two decades ago and have become widely useful. The most successful drug is Humira (biologic). An arthritis medication with 11 approved indications, including Crohn’s disease (CD), Ulcerative Colitis (UC), Psoriatic Arthritis (PsA), and Psoriasis, is currently the world’s best-selling drug for the treatment of autoimmune diseases. However, more recently, agents that simultaneously block multiple pathogenic cytokines via inhibition of the downstream Janus kinase (JAK)-signal transducer and activator of transcription pathway have emerged and are becoming increasingly important. These small-molecule inhibitors, collectively termed JAK inhibitors, are US Food and Drug Administration – approved in a few autoimmune/inflammatory disorders and are being evaluated in many others. JAKs offer a new efficacious treatment option to patients who have already gone through anti-TNF and other biologic therapies. JAKs are given via oral route of administration (RoA), implying that patients are keener to participate in clinical trials and more likely to select an oral RoA over an SC or IV option. Additionally, patients do not need to be instructed on how to inject themselves, nor do they need to arrange transportation to injection sites.


Apart from most extensively studied Jak inhibitors, compounds targeting other kinases such as Syk, Src-family kinases, Tyk2, or Btk are also expected to emerge as new therapeutics for autoimmune disease. Among the emerging candidates, the hopes are high for Tyk2 inhibition. The toxicity issues with Jaks are assumed to be due to these drugs’ far-reaching activity across several Jak subtypes. By not striking Jak2 and 3 it is thought that Tyk2 inhibitors could also sidestep these adverse events.


Already established treatment regimen including biologics for a range of autoimmune diseases is a significant roadblock to establishing kinase inhibitors in the market. In terms of safety, biologics compared to JAK inhibitors offer a “better” benefit-to-risk ratio, with no risk for drug-drug interactions and no monitoring needed. The first-generation JAKs, despite proven efficacious both in clinical trials and in the clinics in treating inflammatory and autoimmune diseases, all are facing an imbalance between safety and efficacy. Also, at present, only limited JAK inhibitors are available in the market compared to biologics which have already established a milestone; hence, treating physician often has biased towards prescribing biologics. Lastly, biosimilars of some of these drugs have already started to enter the market and will likely increase competition to kinase inhibitors.


Key Findings

This section includes a glimpse of the Global Kinase Inhibitor in Autoimmune Diseases market across the globe. The global market size was USD 4,005.6 million in 2020.


The United States: Market Outlook

This section provides Global Kinase Inhibitor in Autoimmune Diseases market size and market size by therapies of Global Kinase Inhibitor in Autoimmune Diseases in the United States.


The United States accounts for the largest market size of Global Kinase Inhibitor in Autoimmune Diseases in comparison to the EU5, Japan, and the rest of the world.


EU-5 Countries: Market Outlook

The total Global Kinase inhibitors in Autoimmune Diseases market size and market size by therapies of Global Kinase inhibitors in Autoimmune Diseases in EU5 are also mentioned.


Japan Market Outlook

The total Global Kinase Inhibitor in Autoimmune Diseases market size and market size by therapies of Global Kinase Inhibitor in Autoimmune Diseases in Japan are also mentioned.


Rest of World Market Outlook

The total Global Kinase Inhibitor in Autoimmune Diseases market size and market size by therapies of Global Kinase Inhibitor in Autoimmune Diseases in rest of world are also mentioned.

Global Kinase Inhibitor in Autoimmune Diseases Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Global Kinase Inhibitor in Autoimmune Diseases market uptake by drugs, patient uptake by therapies, and sales of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Global Kinase Inhibitor in Autoimmune Diseases Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Global Kinase Inhibitor in Autoimmune Diseases key players involved in developing targeted therapeutics.


Major players include Ritlecitinib/PF‐06651600 (Pfizer), Abrocitinib (Pfizer), Ruxolitinib (Incyte Corporation), GLPG3970 (Galapagos NV), ATI-450 (Aclaris Therapeutics), OST-122 (Oncostellae), whose key products are expected to get launched in the US market by 20XX.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Global Kinase Inhibitor in Autoimmune Diseases emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs' and SMEs’ opinion working in the Global Kinase Inhibitor in Autoimmune Diseases domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Global Kinase Inhibitor in Autoimmune Diseases market trend. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Global Kinase Inhibitor in Autoimmune Diseases market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Global Kinase Inhibitor in Autoimmune Diseases, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Global Kinase Inhibitor in Autoimmune Diseases treatment across the globe.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Global Kinase Inhibitor in Autoimmune Diseases is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Global Kinase Inhibitor in Autoimmune Diseases market, historical and forecasted, is included in the report, covering drug outreach in the globe.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the worldwide Global Kinase Inhibitor in the Autoimmune Diseases market

Report Highlights

  • In the coming years, the Global Kinase Inhibitor in Autoimmune Diseases market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Global Kinase Inhibitor in Autoimmune Diseases R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Global Kinase Inhibitor in Autoimmune Diseases. The launch of emerging therapies will significantly impact The Global Kinase Inhibitor in the Autoimmune Diseases market
  • A better understanding of disease pathogenesis will also help develop novel therapeutics for Global Kinase Inhibitor in Autoimmune Diseases.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Global Kinase Inhibitor in Autoimmune Diseases Report Insights

  • Therapeutic Approaches
  • Global Kinase Inhibitor in Autoimmune Diseases Pipeline Analysis
  • Global Kinase Inhibitor in Autoimmune Diseases Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Global Kinase Inhibitor in Autoimmune Diseases Report Key Strengths

  • 10-years Forecast
  • Global Coverage
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Global Kinase Inhibitor in Autoimmune Diseases Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Global Kinase Inhibitor in Autoimmune Diseases Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Global Kinase Inhibitor in Autoimmune Diseases total market Size and market Size by therapies across the globe during the forecast period (2018–2030)?
  • What are the key findings pertaining to the market across the globe, and which country will have the largest Global Kinase Inhibitor in Autoimmune Diseases market Size during the forecast period (2018–2030)?
  • At what CAGR, the Global Kinase Inhibitor in Autoimmune Diseases market is expected to grow in the globe during the forecast period (2018–2030)?
  • What would be the Global Kinase Inhibitor in Autoimmune Diseases market outlook across the globe during the forecast period (2018–2030)?
  • What would be the Global Kinase Inhibitor in Autoimmune Diseases market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the Global Kinase Inhibitor in Autoimmune Diseases marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing Global Kinase Inhibitor in treating Autoimmune Diseases
  • How many emerging Global Kinase Inhibitor therapies are in the mid-stage and late stages of development for the treatment of autoimmune diseases?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Global Kinase Inhibitor in Autoimmune Diseases therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Global Kinase Inhibitor in Autoimmune Diseases and their status?
  • What are the key designations that have been granted for the emerging therapies for Global Kinase Inhibitor in Autoimmune Diseases?
  • What are the global historical and forecasted market for Global Kinase Inhibitor in Autoimmune Diseases?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Global Kinase Inhibitor in Autoimmune Diseasesmarket
  • To understand the future market competition in the Global Kinase Inhibitor in Autoimmune Diseasesmarket and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Global Kinase Inhibitor in Autoimmune Diseases across the globe
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Global Kinase Inhibitor in the Autoimmune Diseases market.
  • To understand the future market competition in the Global Kinase Inhibitor in Autoimmune Diseases market.

1.  Key Insights

2.  Report Introduction

3.  GKIAD Market Overview at a Glance

3.1. Market Share (%) Distribution of GKIAD in 2018

3.2. Market Share (%) Distribution of GKIAD in 2030

4.  Executive Summary of Global Kinase Inhibitors in Autoimmune Disease (GKIAD)

5.  Global Kinase Inhibitor in Autoimmune Disorders

5.1. Introduction to Immunological Disorders

5.2. Kinase Inhibitors in Autoimmune Diseases

5.3. Various Immunological Disorders

5.3.1.Rheumatoid Arthritis (RA)

5.3.2.Disease Background and Overview

5.3.2.1. Stages of RA

5.3.2.2. Types of RA

5.3.2.3. Signs and Symptoms of RA

5.3.2.4. Risk Factors and Causes of RA

5.3.2.5. Pathogenesis of RA

5.3.3.Current Treatment Practices: RA

5.3.3.1. Medications

5.3.3.2. Supportive Treatment

5.3.3.3. Surgery

5.3.3.4. Treatment Algorithm

5.3.3.5. Guideline of RA

5.3.4.Psoriasis

5.3.5.Disease Background and Overview

5.3.5.1. Causes and Triggers

5.3.5.2. Locations

5.3.5.3. Types of Psoriasis

5.3.5.4. Pathophysiology

5.3.6.Treatment and Management

5.3.6.1. Topicals

5.3.6.2. Phototherapy

5.3.6.3. Systemics

5.3.7.Crohn’s Disease (CD)

5.3.8.Disease Background and Overview

5.3.8.1. Types of CD

5.3.8.2. Classification of CD

5.3.8.3. Signs and Symptoms of CD

5.3.8.4. Risk Factors and Causes of CD

5.3.8.5. Pathophysiology of CD

5.3.9.Current Treatment Practices: CD

5.3.9.1. Treatment Algorithm of CD

5.3.9.2. Drug Therapies

5.3.9.3. Surgery

5.3.9.4. Diet and Nutrition

5.3.9.5. Treatment and Management Guidelines of CD

5.3.10. Ulcerative Colitis (UC):

5.3.11. Disease Background and Overview

5.3.11.1. Types of UC

5.3.11.2. Classification of UC

5.3.11.3. Signs and Symptoms of UC

5.3.11.4. Risk Factors and Causes of UC

5.3.11.5. Pathophysiology of UC

5.3.11.6. Severity Scoring System

5.3.12. Current Treatment Practices: UC

5.3.12.1. Treatment Algorithm of UC

5.3.12.2. Drug Therapies

5.3.12.3. Other therapies

5.3.12.4. Surgery

5.3.12.5. Diet and Nutrition

5.3.12.6. Treatment and Management Guidelines of CD

5.3.13. Psoriatic Arthritis (PsA)

5.3.14. Disease Background and Overview

5.3.14.1. Clinical Manifestations

5.3.14.2. Classification

5.3.14.3. Risk Factors

5.3.14.4. Pathogenesis of PSA

5.3.15. Treatment and Management

5.3.15.1. ACR/NPF Recommendations for Psoriatic arthritis

5.3.15.2. Summary of differences in recommendations

5.3.15.3. EULAR Recommendations

5.3.16. Other Immunological disorder

5.3.17. Sjogren Syndrome

5.3.18. Atopic Dermatitis

6.  Marketed Drugs

6.1. Key cross Competition

6.2. Xeljanz (Tofacitinib): Pfizer

6.2.1.Product Description

6.2.2.Regulatory Milestones for Rheumatoid Arthritis:

6.2.3.Regulatory Milestones for Psoriatic Arthritis:

6.2.4.Regulatory Milestones for Ulcerative Colitis

6.2.5.Regulatory Milestones for Polyarticular Course juvenile idiopathic arthritis

6.2.6.Safety and Efficacy of Xeljanz for Rheumatoid Arthritis

6.2.7.Safety and Efficacy of Xeljanz for Psoriatic Arthritis

6.2.8.Safety and Efficacy of Xeljanz for Polyarticular Course juvenile idiopathic arthritis

6.2.9.Side effects of Xeljanz

6.2.10. Product Profile

6.3. Olumiant: Eli Lily and Incyte Corporation

6.3.1.Product Description

6.3.2.Regulatory Milestone for rheumatoid arthritis

6.3.3.Regulatory Milestone for Atopic Dermatitis

6.3.4.Safety and Efficacy for Rheumatoid arthritis

6.3.5.Safety and Efficacy for Atopic Dermatitis

6.3.6.Side effects of Olumiant

6.3.7.Product Profile

6.4. RINVOQ: AbbVie

6.4.1.Product Description

6.4.2.Regulatory Milestone

6.4.3.Safety and Efficacy for RA

6.4.4.Safety and Efficacy for PsA

6.4.5.Safety and Efficacy for Ankylosing spondylitis

6.4.6.Side effects of RINVOQ

6.4.7.Other developmental activities

6.4.8.Clinical Development

6.4.9.Clinical trial information

6.4.10. Safety and Efficacy

6.4.11. Product Profile

6.5. Jyseleca: Gilead Sciences

6.5.1.Product Description

6.5.2.Regulatory Milestone

6.5.3.Safety and Efficacy

6.5.4.Side Effects of Jyseleca

6.5.5.Other development activities

6.5.6.Clinical Development

6.5.7.Clinical trial information

6.5.8.Safety and Efficacy

6.5.9.Product Profile

6.6. Smyraf: Astellas Pharma

6.6.1.Product Description

6.6.2.Regulatory Milestone

6.6.3.Safety and Efficacy

6.6.4.Side Effects of Smyraf

6.6.5.Product Profile

6.7. Corectim: Japan Tobacco and Torii Pharmaceutical

6.7.1.Product Description

6.7.2.Regulatory Milestone

6.7.3.Safety and Efficacy

6.7.4.Side Effects of CORECTIM Ointment 0.5%

6.7.5.Product Profile

7.  Emerging Therapies

7.1. Key Cross Competition

7.2. Ritlecitinib: Pfizer

7.2.1.Drug Description

7.2.2.Clinical Development

7.2.3.Clinical trial information

7.2.4.Safety and Efficacy

7.2.5.Product Profile

7.3. Ritlecitinib/PF-06650833/ Tofacitinib: Pfizer

7.3.1.Drug Description

7.3.2.Clinical Development

7.3.3.Clinical trial information

7.3.4.Product Profile

7.4. SHR0302: Reistone Biopharma

7.4.1.Drug Description

7.4.2.Other development Activities

7.4.3.Clinical Development

7.4.4.Clinical trial information

7.4.5.Safety and Efficacy

7.4.6.Product Profile

7.5. Abrocitinib: Pfizer

7.5.1.Drug Description

7.5.2.Other Development Activities

7.5.3.Clinical Development

7.5.4.Clinical trial information

7.5.5.Safety and Efficacy

7.5.6.Product Profile

7.6. Ruxolitinib: Incyte Corporation

7.6.1.Drug Description

7.6.2.Other Development Activities

7.6.3.Clinical Development

7.6.4.Clinical trial information

7.6.5.Safety and Efficacy

7.6.6.Product Profile

7.7. Branebrutinib: Bristol Myers Squibb

7.7.1.Drug Description

7.7.2.Other Development Activities

7.7.3.Clinical Development

7.7.4.Clinical trial information

7.7.5.Safety and Efficacy

7.7.6.Product Profile

7.8. GLPG3970: Galapagos NV

7.8.1.Drug Description

7.8.2.Other Development Activity

7.8.3.Clinical Development

7.8.4.Clinical trial information

7.8.5.Product Profile

7.9. ATI-450: Aclaris Therapeutics

7.9.1.Drug Description

7.9.2.Other Developmental Activities

7.9.3.Clinical Development

7.9.4.Clinical trial information

7.9.5.Safety and Efficacy

7.9.6.Product Profile

7.10. TAS5315: Tahio Pharma

7.10.1. Drug Description

7.10.2. Clinical Development

7.10.3. Clinical trial information

7.10.4. Product Profile

7.11. OST-122: Oncostellae

7.11.1. Drug Description

7.11.2. Clinical Development

7.11.3. Clinical trial information

7.11.4. Product Profile

7.12. Remibrutinib: Novartis Pharmaceuticals

7.12.1. Drug Description

7.12.2. Clinical Development

7.12.3. Clinical trial information

7.12.4. Product Profile

7.13. ATI-1777: Aclaris Therapeutics

7.13.1. Drug Description

7.13.2. Other Developmental Activities

7.13.3. Clinical Development

7.13.4. Clinical trial information

7.13.5. Product Profile

7.14. Izencitinib: Theravance Biopharma and Janssen (Johnson & Johnson)

7.14.1. Drug Description

7.14.2. Other Developmental Activities

7.14.3. Clinical Development

7.14.4. Clinical trial information

7.14.5. Product Profile

7.15. PF-06826647: Pfizer

7.15.1. Drug Description

7.15.2. Clinical Development

7.15.3. Clinical Trials Information

7.15.4. Safety and Efficacy

7.15.5. Product Profile

7.16. Deucravacitinib (BMS-986165): BMS

7.16.1. Drug Description

7.16.2. Clinical Development

7.16.3. Clinical Trials Information

7.16.4. Safety and Efficacy

7.16.5. Product Profile

7.17. PF-06700841 (Brepocitinib): Pfizer

7.17.1. Drug Description

7.17.2. Clinical Development

7.17.3. Clinical Trials Information

7.17.4. Safety and Efficacy

7.17.5. Product Profile

7.18. Belumosudil: Kadmon Pharmaceuticals

7.18.1. Drug Description

7.18.2. Other Clinical Development

7.18.3. Clinical Development

7.18.4. Clinical Trials Information

7.18.5. Safety and Efficacy

7.18.6. Product Profile

7.19. Elsubrutinib: AbbVie

7.19.1. Drug Description

7.19.2. Clinical Development

7.19.3. Clinical Trials Information

7.19.4. Product Profile

8.  Global Kinase Inhibitors in Autoimmune Disease: Market Analysis

8.1. Key Findings

8.2. Market Size of GKIAD

8.3. Market Outlook

8.4. Corectim: Japan Tobacco and Torii Pharmaceutical

8.5. The United States

8.5.1.Total Market Size of GKIAD in the United States

8.5.2.Market Size of GKIAD by Therapies in the United States

8.6. EU-5

8.6.1.Total Market Size of GKIAD in EU5

8.6.2.Market Size of GKIAD by Therapies in EU5

8.7. Japan

8.7.1.Total Market size of GKIAD in Japan

8.7.2.Market Size of GKIAD by Therapies in Japan

8.8. Rest of World (RoW)

8.8.1.Total Market size of GKIAD in RoW

8.8.2.Market Size of GKIAD by Therapies in Japan

9.  Key Opinion Leaders

10. Market Drivers

11. Market Barrier

12. SWOT Analysis

13. Unmet Needs

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

List of Table

Table 1: Summary of GKIAD, Market and Key Events (2018–2030)

Table 2: Mechanisms of Kinase Inhibition

Table 3: Examples of painkillers and NSAIDs

Table 4: Psoriasis-Associated Comorbidities

Table 5: Difference between Crohn’s Disease and Ulcerative Colitis

Table 6: Vienna and Montreal classification for CD

Table 7: Genes with functions associated with CD

Table 8: Cytokines associated with CD

Table 9: Difference between Crohn’s Disease and Ulcerative Colitis

Table 10: Montreal classification of the extent of U

Table 11: Montreal classification of severity of UC

Table 12: Mayo Severity Score

Table 13: Medical Therapy for UC

Table 14: 2018 ACR/NPF Recommendations for the initial treatment for active psoriatic arthritis who are OSM‐ and other naïve treatment

Table 15: 2018 ACR/NPF Recommendations for active PsA despite treatment with a TNFi biologics

Table 16: 2018 ACR/NPF Recommendations for active PsA despite treatment with an IL‐17i or an IL‐12/23i biologics

Table 17: 2018 ACR/NPF Recommendations for PsA including treat‐to‐target, active axial disease, enthesitis, or active inflammatory bowel disease

Table 18: 2018 ACR/NPF Recommendations for PsA and comorbidities, including concomitant diabetes and serious recurrent infections

Table 19: 2018 ACR/NPF Recommendations for non-pharmacologic interventions in patients with active PsA regardless of pharmacologic treatment status

Table 20: Summary of differences in recommendations

Table 21: 2019 EULAR recommendations for the pharmacological management of psoriatic arthritis

Table 22: Key cross of the Marketed drugs

Table 23: Upadacitinib, Clinical Trial Description, 2021

Table 24: Filgotinib, Clinical Trial Description, 2021

Table 25: Key assets

Table 26: Key assets

Table 27: Other assets

Table 28: Ritlecitinib, Clinical Trial Description, 2021

Table 29: Ritlecitinib PF-06650833/ Tofacitinib, Clinical Trial Description, 2021

Table 30: SHR0302, Clinical Trial Description, 2021

Table 31: Abrocitinib, Clinical Trial Description, 2021

Table 32: Ruxolitinib, Clinical Trial Description, 2021

Table 33: Branebruitinib, Clinical Trial Description, 2021

Table 34: GLPG3970, Clinical Trial Description, 2021

Table 35: ATI-450, Clinical Trial Description, 2021

Table 36: TAS5315, Clinical Trial Description, 2021

Table 37: OST-122, Clinical Trial Description, 2021

Table 38: LOU064, Clinical Trial Description, 2021

Table 39: ATI-1777, Clinical Trial Description, 2021

Table 40: TD-1473, Clinical Trial Description, 2021

Table 41: PF-06826647, Clinical Trial Description, 2021

Table 42: Deucravacitinib, Clinical Trial Description, 2021

Table 43: Brepocitinib, Clinical Trial Description, 2021

Table 44: KD025, Clinical Trial Description, 2021

Table 45: ABBV-105, Clinical Trial Description, 2021

Table 46: Global Market Size of Kinase Inhibitors in Autoimmune Disorders in USD Million (2018–2030)

Table 47: The United States Market Size of GKIAD in USD Million (2018–2030)

Table 48: United States Market Size of GKIAD by Therapies in USD Million (2018–2030)

Table 49: Eu5 Market Size of GKIAD in USD Million (2018–2030)

Table 50: EU5 Market Size of GKIAD by Therapies in USD Million (2018–2030)

Table 51: Japan Market Size of GKIAD in USD Million (2018–2030)

Table 52: Japan Market Size of GKIAD by Therapies in USD Million (2018–2030)

Table 53: RoW Market Size of GKIAD in USD Million (2018–2030)

Table 54: Market Size of GKIAD by Therapies in RoW in USD Million (2018–2030)"

List of Figures

Figure 1: Mechanism of Autoimmunity

Figure 2: Structure of JAK and STAT Molecule

Figure 3: Rheumatoid Arthritis (RA) Distressed Area

Figure 4: Stages of Rheumatoid Arthritis

Figure 5: Types of Rheumatoid Arthritis

Figure 6: Sign and Symptoms of RA

Figure 7: Factors contributing to RA development

Figure 8: Associations and links for RA

Figure 9: Initiation and Progression of RA

Figure 10: Clinical manifestations of RA

Figure 11: Treatment Overview of RA

Figure 12: Molecular mode of action of Janus activated kinase (JAK) inhibitors Tofacitinib and Baricitinib

Figure 13: Recommendations for the treatment of early rheumatoid arthritis (RA), defined as a disease duration of <6 months

Figure 14: Treatment algorithm for established RA (>6 months)

Figure 15: EULAR RA management recommendations in the form of an algorithm

Figure 16: Drug treatment for rheumatoid arthritis by NICE

Figure 17: Synopsis on psoriasis as a chronic disease with a high comorbidity

Figure 18: Triggers that can cause Psoriasis

Figure 19: Mechanism of Psoriasis

Figure 20: Overall Treatment Approach for Plaque Psoriasis

Figure 21: Inflammatory bowel disease subsets

Figure 22: Difference between CD and Ulcerative Colitis

Figure 23: Types of CD

Figure 24: Signs and Symptoms

Figure 25: Causes and risk factors of CD

Figure 26: Immuno-mediated pathogenesis of CD

Figure 27: Treatment algorithm of CD

Figure 28: Difference between CD and Ulcerative Colitis

Figure 29: Types of UC

Figure 30: Signs and Symptoms

Figure 31: Complications of UC

Figure 32: Risk Factors of UC

Figure 33: General factors associated with increased susceptibility of UC

Figure 34: Treatment algorithm of Severe UC

Figure 35: Treatment algorithm of Mild to moderate UC

Figure 36: Surgically created ""J"" shaped reservoir

Figure 37: Clinical Presentations

Figure 38: Classification of PsA

Figure 39: Risk Factors

Figure 40: Key cell types and secretion of key inflammatory mediators in psoriatic arthritis

Figure 41: Adaptive and innate immune cells and activated pathways in psoriatic arthritis

Figure 42: Pharmacologic, non-pharmacologic, and symptomatic therapies for psoriatic arthritis

Figure 43: The EULAR 2019 algorithm for treatment of PsA with pharmacological non-topical treatments

Figure 44: Psoriatic Arthritis Treatment Pathway Following Inadequate Response to DMARDs (NICE)

Figure 45: Market Size of GKIAD in USD Million (2018–2030)

Figure 46: Market Size of GKIAD in the United States, USD Million (2018–2030)

Figure 47: The United States Market Size of GKIAD by Therapies in USD Million (2018–2030)

Figure 48: Market Size of GKIAD in EU5, USD Million (2018–2030)

Figure 49: EU5 Market Size of GKIAD by Therapies in USD Million (2018–2030)

Figure 50: Market Size of GKIAD in Japan, USD Million (2018–2030)

Figure 51: Japan Market Size of GKIAD by Therapies in USD Million (2018–2030)

Figure 52: Market Size of GKIAD in RoW, USD Million (2018–2030)

Figure 53: RoW Market Size of GKIAD by Therapies in USD Million (2018–2030)

Xeljanz (Tofacitinib): Pfizer

Olumiant: Eli Lily and Incyte Corporation

RINVOQ: AbbVie

Jyseleca: Gilead Sciences

Smyraf: Astellas Pharma

Corectim: Japan Tobacco and Torii Pharmaceutical

Ritlecitinib: Pfizer

Ritlecitinib/PF-06650833/ Tofacitinib: Pfizer

SHR0302: Reistone Biopharma

Ruxolitinib: Incyte Corporation

Branebrutinib: Bristol Myers Squibb

GLPG3970: Galapagos NV

ATI-450: Aclaris Therapeutics

TAS5315: Tahio Pharma

OST-122: Oncostellae

Remibrutinib: Novartis Pharmaceuticals

ATI-1777: Aclaris Therapeutics

Izencitinib: Theravance Biopharma and Janssen (Johnson & Johnson)

PF-06826647: Pfizer

Deucravacitinib (BMS-986165): BMS

PF-06700841 (Brepocitinib): Pfizer

Belumosudil: Kadmon Pharmaceuticals

Elsubrutinib: AbbVie

  • Tags:
  • Global Kinase Inhibitor market
  • Global Kinase Inhibitor market res...
  • Global Kinase Inhibitor Companies
  • Global Kinase Inhibitor market tre...
  • Global Kinase Inhibitor market for...
  • Global Kinase Inhibitor market sha...
  • Global Kinase Inhibitor pipeline
  • Global Kinase Inhibitor treatment...
  • Global Kinase Inhibitor drugs
  • Global Kinase Inhibitor sales fore...
  • Global Kinase Inhibitor market siz...
  • Global Kinase Inhibitor disease
  • Global Kinase Inhibitor epidemiolo...
  • Global Kinase Inhibitor

Forward to Friend

Need A Quote